1. Developed new platform for extrahepatic delivery of siRNAs to treat conditions related certain hormonal disorders.2. Conducted SAR of small molecules, linear peptides and cyclic peptides to determine the efficiency of targetingConducted SAR of PK modifiers and demonstrated synergistic effects of PK modifiers with targeting ligands. 3. Peptide synthesis utilizing both manual and high throughput automated peptide synthesizers.4. Extensive experience with purification of peptides using prep HPLC and characterization of peptides using MALDI-TOF MS, ESI, LC-MS.

1. Prepared novel phosphoramidites to optimize siRNA efficacy2. Synthesized capped, uncapped, locked and unlocked nucleosides and their corresponding 3. phosphonamidites.3. Designed novel endosomal escape domains and prepared small molecules and peptides to enhance the endosomal escape of siRNAs4. Conducted post synthetic modifications of siRNAs on CPGs as a method for conjugation of small molecules and peptides to siRNAs5. Extensive experience in analyzing siRNAs after cleavage and deprotection

1. Total synthesis of complex natural products that has upto 6 stereocenters2. Identified ATPs synthase as a target for phomoxanthone A by photoaffinity labelling.3. Synthesized complex analogs of phomoxanthone A and Gonytolide A to identify their pharamacophores. Demonstrated significantly structurally-simplified analogs of these natural products will exhibit good biological properties similar to their parent compounds.4. Conducted structure-guided SAR of Phomoxanthone A to achieve specific inhibition with a Ki50 of 7 μM.5. Developed a method for intramolecular Morita-Baylis-Hillman reaction to access privileged tetrahydroxanthones from simple chromenones for SAR studies.The research resulted in 1 patent, 4 publications, 2 conference presentations at national conferences of the American Chemical Society.

1. Developed a generalized novel benzannulation methodology en route to prepare diterpenoids such as triptonide and triptolide.2. The research resulted in 3 conference presentations.

1. Developed very potent HIV-1 entry inhibitors that down-modulate CD4 expression.2. Successfully developed reliable methodology for unconventional macrocyclization of disulfonamides using Pd catalyzed Tsuji-Trost conditions to prepare cycolotriazadisulfonamide (CADA) head analogs as HIV-1 entry inhibitors.3. Successfully developed structure guided SAR to investigate the bioactive conformation of CADA compounds4. Developed methodology for palladium catalyzed macrocyclization of disulfonamides.5. This research resulted in 3 publications and 5 ACS conference presentations.